InvestorsObserver
×
News Home

Is it Time to Dump 89bio Inc (ETNB) Stock After it Is Up 15.35% in a Week?

Wednesday, April 21, 2021 10:16 AM | InvestorsObserver Analysts

Mentioned in this article

Is it Time to Dump 89bio Inc (ETNB) Stock After it Is Up 15.35% in a Week?

The market has been high on 89bio Inc (ETNB) stock recently. ETNB gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,bullish
89bio Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ETNB!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.

InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.

For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ETNB Stock Today?

89bio Inc (ETNB) stock is trading at $27.43 as of 10:02 AM on Wednesday, Apr 21, a gain of $1.62, or 6.28% from the previous closing price of $25.81. The stock has traded between $26.36 and $27.50 so far today. Volume today is light. So far 24,212 shares have traded compared to average volume of 96,874 shares.

To see the top 5 stocks in the Biotechnology industry click here.

More About 89bio Inc

89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, BIO89-100, is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast growth factor 21 (FGF21) is developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Click Here to get the full Stock Score Report on 89bio Inc (ETNB) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App